In 2025, EudraVigilance received over 1.7 million adverse drug reaction reports. Therefore, effective safety monitoring requires more than collecting individual case reports. The types of pharmacovigilance determine how companies identify, investigate, and manage emerging medicine risks. However, active, passive, and targeted approaches collect safety evidence differently. Understanding these methods helps PV teams strengthen signal detection, regulatory compliance, and inspection readiness.
Table of Contents
What Are the Types of Pharmacovigilance?
Pharmacovigilance uses several approaches to detect, assess, and manage medicine-related risks. Passive pharmacovigilance mainly relies on reports submitted by healthcare professionals, patients, and companies. In contrast, active pharmacovigilance proactively collects safety data from defined populations or data sources. However, these broad approaches include several specific methods. Spontaneous reporting, registries, structured post-marketing studies, and targeted monitoring all support the wider drug safety system. Therefore, companies often combine methods to strengthen signal detection and ongoing benefit-risk assessment.
Why Do Drug Safety Monitoring Methods Matter for Compliance?
Drug safety monitoring methods help companies collect complete and reliable safety data throughout a medicine’s lifecycle. Therefore, strong monitoring supports faster signal detection and more accurate benefit-risk evaluation. It also helps teams identify when regulatory action, label updates, or further investigation may be necessary. Moreover, well-documented surveillance activities create clear evidence for audits and inspections. As a result, effective drug safety monitoring strengthens compliance, traceability, and patient protection.
How Pharmacovigilance Methods Generate Safety Evidence
Pharmacovigilance methods generate safety evidence by collecting, reviewing, and connecting data from different sources. Passive systems capture reported safety concerns, while active methods search more systematically for adverse events. In addition, structured studies and targeted follow-up can provide richer clinical context. Together, these approaches help safety teams identify patterns, assess possible signals, and support evidence-based regulatory decisions.
The following monitoring approaches show how different pharmacovigilance methods contribute to stronger and more complete safety evidence.
- Passive Pharmacovigilance and Spontaneous Reporting (Available PDF)
- Active Pharmacovigilance and Structured Surveillance (Available PDF)
- Signal Detection Across Drug Safety Data Sources (Available PDF)
- Cohort Event Monitoring and Targeted Follow-Up (Available PDF)
This infographic shows how passive and active pharmacovigilance collect safety evidence differently and why combining both approaches can strengthen drug safety surveillance.
Passive Pharmacovigilance and Spontaneous Reporting (Available PDF)
Passive pharmacovigilance collects suspected adverse reaction reports to support signal detection, but incomplete reporting can limit analysis.
Download GVP Module VI: Suspected Adverse Reaction Reporting (Rev 2) here.
Active Pharmacovigilance and Structured Surveillance (Available PDF)
Active pharmacovigilance proactively collects safety data through studies, registries, healthcare databases, and structured follow-up. This approach provides more systematic evidence for evaluating known or emerging medicine risks.
Signal Detection Across Drug Safety Data Sources (Available PDF)
Signal detection reviews multiple data sources to identify new safety concerns or changes in known risks. Teams then validate, prioritize, and assess signals before deciding whether regulatory action is needed.
Cohort Event Monitoring and Targeted Follow-Up (Available PDF)
Cohort event monitoring tracks adverse events in defined patient groups, while targeted follow-up adds clinical detail for stronger safety assessment.
Download the Practical Handbook on Pharmacovigilance for TB Medicines here.
How Do Pharmacovigilance Methods Compare in Practice?
No single pharmacovigilance method captures every safety risk. Passive systems provide broad real-world coverage, while active methods collect safety information more systematically. In addition, structured studies can investigate specific risks and quantify associations. Therefore, companies combine different methods according to the medicine, population, safety concern, and regulatory need.
The table compares how major pharmacovigilance methods collect data, the evidence they generate, and their practical strengths, limitations, and regulatory value.
| Pharmacovigilance Method | How It Collects Safety Information | Evidence Generated | Major Strengths | Main Limitations | Regulatory Value |
|---|---|---|---|---|---|
|
Spontaneous Reporting |
Patients, healthcare professionals, and companies submit suspected adverse reaction reports. |
Individual case reports and potential safety signals. |
Broad coverage; useful for rare or unexpected reactions. |
Under-reporting, incomplete cases, and reporting bias. |
Supports routine safety reporting and signal detection. |
|
Active Surveillance |
Teams proactively collect adverse-event data from defined populations or data sources. |
Systematic safety data with clearer exposure information. |
More complete case capture and structured monitoring. |
Requires more resources, systems, and follow-up. |
Supports focused monitoring of important safety concerns. |
|
Cohort Event Monitoring |
Teams follow a defined group of exposed patients and systematically record clinical events. |
Event frequencies, patterns, and patient-level safety information. |
Links events to a known exposed population. |
Needs organised follow-up and sufficient cohort size. |
Supports targeted post-marketing surveillance and signal assessment. |
|
Post-Authorisation Safety Studies |
Observational studies use healthcare databases, registries, or primary data to investigate specific risks. |
Quantitative evidence on risk, associations, and affected populations. |
Tests specific safety questions and supports risk estimation. |
Confounding, bias, and data quality can affect results. |
Supports benefit-risk evaluation and regulatory decision-making. |
This infographic compares how active and passive pharmacovigilance collect safety data, highlighting where each approach performs well and where additional monitoring may be needed.
How Should Companies Select a Pharmacovigilance Method?
Companies should choose a pharmacovigilance method according to the safety question, medicine profile, and available evidence. For example, rare events may require broad spontaneous reporting, while defined risks may need active surveillance or structured studies. In addition, patient population, exposure data, lifecycle stage, and regulatory commitments can shape the monitoring strategy. Therefore, the most effective approach is often a justified combination of methods that closes specific safety-data gaps.
Final Words
In 2024, EMA inspectors recorded 87 deficiencies during CHMP-requested human medicines pharmacovigilance inspections, including 29 major findings. Notably, common problem areas included adverse reaction management, quality systems, and the PSMF. Therefore, companies should manage the types of pharmacovigilance as connected parts of an inspection-ready safety system. Strong data flow, documented oversight, and timely follow-up remain essential for reliable drug safety and regulatory compliance.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
Inspectors expect an up-to-date PSMF, controlled procedures, safety records, training evidence, audit results, and CAPA documentation. Companies should also prove that documented pharmacovigilance processes work consistently in practice.
Inspectors check whether teams capture, assess, follow up, code, and report adverse drug reactions correctly and on time. They also review backlogs, missing cases, data quality, and controls for serious or high-priority reports.
Companies should maintain documented signal detection methods, review records, assessment decisions, and evidence from relevant safety data sources. Inspectors may also examine how teams validate, prioritize, escalate, and track signals through benefit-risk evaluation.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.